Literature DB >> 19697126

Neurotoxic effects of methamphetamine.

Bessy Thrash1, Senthilkumar S Karuppagounder, Subramaniam Uthayathas, Vishnu Suppiramaniam, Muralikrishnan Dhanasekaran.   

Abstract

In Parkinson's disease, depletion of dopamine in the striatum leads to various symptoms such as tremor, rigidity and akinesia. Methamphetamine use has significantly increased in USA and around the world and there are several reports showing that its long-term use increases the risk for dopamine depletion. However, the toxic mechanisms of methamphetamine are not well understood. This study was undertaken to gain greater mechanistic understanding of the toxicity induced by methamphetamine. We evaluated the effect of methamphetamine on the generation of reactive oxygen species, mitochondrial monoamine oxidase, complex I & IV activities. Behavioral analysis evaluated the effect on catalepsy, akinesia and swim score. Neurotransmitter levels were evaluated using high pressure liquid chromatography (HPLC) electrochemical detection (ECD). Results showed that methamphetamine caused significant generation of reactive oxygen species and decreased complex I activity in the mitochondria leading to dopamine depletion in the striatum.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19697126     DOI: 10.1007/s11064-009-0042-5

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  42 in total

1.  U-95666E: a potential anti-parkinsonian drug with anxiolytic activity.

Authors:  V H Sethy; B R Ellerbrock; H Wu
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  1997-07       Impact factor: 5.067

Review 2.  Therapeutic role of coenzyme Q(10) in Parkinson's disease.

Authors:  Clifford W Shults
Journal:  Pharmacol Ther       Date:  2005-04-21       Impact factor: 12.310

3.  Effect of acute and chronic methamphetamine treatment on tyrosine hydroxylase activity in brain and adrenal medulla.

Authors:  H C Fibiger; E G Mogeer
Journal:  Eur J Pharmacol       Date:  1971-10       Impact factor: 4.432

Review 4.  Parkinson's disease.

Authors:  C D Marsden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-06       Impact factor: 10.154

5.  Free radical production induced by methamphetamine in rat striatal synaptosomes.

Authors:  David Pubill; Carlos Chipana; Antonio Camins; Mercè Pallàs; Jordi Camarasa; Elena Escubedo
Journal:  Toxicol Appl Pharmacol       Date:  2005-04-01       Impact factor: 4.219

6.  Methamphetamines pretreatment and the vulnerability of the striatum to methamphetamine neurotoxicity.

Authors:  S Stephans; B Yamamoto
Journal:  Neuroscience       Date:  1996-06       Impact factor: 3.590

7.  SKF-38393, a dopamine receptor agonist, attenuates 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity.

Authors:  D Muralikrishnan; M Ebadi
Journal:  Brain Res       Date:  2001-02-23       Impact factor: 3.252

Review 8.  The oxidant stress hypothesis in Parkinson's disease: evidence supporting it.

Authors:  S Fahn; G Cohen
Journal:  Ann Neurol       Date:  1992-12       Impact factor: 10.422

Review 9.  Current research on methamphetamine-induced neurotoxicity: animal models of monoamine disruption.

Authors:  Taizo Kita; George C Wagner; Toshikatsu Nakashima
Journal:  J Pharmacol Sci       Date:  2003-07       Impact factor: 3.337

Review 10.  Oxidative mechanisms in nigral cell death in Parkinson's disease.

Authors:  P Jenner
Journal:  Mov Disord       Date:  1998       Impact factor: 10.338

View more
  21 in total

1.  The synthesis of haptens and their use for the development of monoclonal antibodies for treating methamphetamine abuse.

Authors:  F Ivy Carroll; Philip Abraham; Paul K Gong; Ramakrishna R Pidaparthi; Bruce E Blough; Yingni Che; Amber Hampton; Melinda Gunnell; Jackson O Lay; Eric C Peterson; S Michael Owens
Journal:  J Med Chem       Date:  2009-11-26       Impact factor: 7.446

Review 2.  Role of Mitochondria in Methamphetamine-Induced Dopaminergic Neurotoxicity: Involvement in Oxidative Stress, Neuroinflammation, and Pro-apoptosis-A Review.

Authors:  Eun-Joo Shin; Hai-Quyen Tran; Phuong-Tram Nguyen; Ji Hoon Jeong; Seung-Yeol Nah; Choon-Gon Jang; Toshitaka Nabeshima; Hyoung-Chun Kim
Journal:  Neurochem Res       Date:  2017-06-07       Impact factor: 3.996

3.  Co-administration of betulinic acid and methamphetamine causes toxicity to dopaminergic and serotonergic nerve terminals in the striatum of late adolescent rats.

Authors:  Bryan Killinger; Mrudang Shah; Anna Moszczynska
Journal:  J Neurochem       Date:  2013-12-03       Impact factor: 5.372

4.  Methamphetamine-induced vascular changes lead to striatal hypoxia and dopamine reduction.

Authors:  Sharanya M Kousik; Steven M Graves; T Celeste Napier; Chaohui Zhao; Paul M Carvey
Journal:  Neuroreport       Date:  2011-12-07       Impact factor: 1.837

5.  PEGylation of a High-Affinity Anti-(+)Methamphetamine Single Chain Antibody Fragment Extends Functional Half-Life by Reducing Clearance.

Authors:  Emily E Reichard; Nisha Nanaware-Kharade; Guillermo A Gonzalez; Shraddha Thakkar; S Michael Owens; Eric C Peterson
Journal:  Pharm Res       Date:  2016-09-12       Impact factor: 4.200

6.  Assessment of therapeutic potential of amantadine in methamphetamine induced neurotoxicity.

Authors:  Bessy Thrash-Williams; Manuj Ahuja; Senthilkumar S Karuppagounder; Subramaniam Uthayathas; Vishnu Suppiramaniam; Muralikrishnan Dhanasekaran
Journal:  Neurochem Res       Date:  2013-08-06       Impact factor: 3.996

7.  Induction of mitochondrial permeability transition (MPT) pore opening and ROS formation as a mechanism for methamphetamine-induced mitochondrial toxicity.

Authors:  Vida Mashayekhi; Mohammad Reza Eskandari; Farzad Kobarfard; Alireza Khajeamiri; Mir-Jamal Hosseini
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-09-24       Impact factor: 3.000

Review 8.  Methamphetamine-induced dopaminergic neurotoxicity as a model of Parkinson's disease.

Authors:  Eun-Joo Shin; Ji Hoon Jeong; Yeonggwang Hwang; Naveen Sharma; Duy-Khanh Dang; Bao-Trong Nguyen; Seung-Yeol Nah; Choon-Gon Jang; Guoying Bing; Toshitaka Nabeshima; Hyoung-Chun Kim
Journal:  Arch Pharm Res       Date:  2021-07-20       Impact factor: 4.946

9.  Dopamine is not essential for the development of methamphetamine-induced neurotoxicity.

Authors:  Jie Yuan; Martin Darvas; Bethany Sotak; George Hatzidimitriou; Una D McCann; Richard D Palmiter; George A Ricaurte
Journal:  J Neurochem       Date:  2010-06-01       Impact factor: 5.372

10.  Gut and brain profiles that resemble pre-motor and early-stage Parkinson's disease in methamphetamine self-administering rats.

Authors:  Amanda L Persons; Brinda Desai Bradaric; Leo P Kelly; Sharanya M Kousik; Steven M Graves; Bryan K Yamamoto; T Celeste Napier
Journal:  Drug Alcohol Depend       Date:  2021-05-20       Impact factor: 4.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.